Caflanone - Flavocure Biotech
Alternative Names: FBL-03G; HLNT-06Latest Information Update: 29 Jun 2026
At a glance
- Originator Flavocure Biotech
- Developer Baylor College of Medicine; Flavocure Biotech
- Class Antineoplastics; Chromones; Phenols; Phenyl ethers; Small molecules
- Mechanism of Action Casein kinase II modulators; Macrophage colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders; Glioblastoma; Multiple myeloma; Pancreatic cancer
Most Recent Events
- 29 Jun 2026 Caflanone is still in preclinical trials for Glioblastoma and Pancreatic-cancer in the USA (Flavocure Biotech Pipeline, June 2026)
- 29 Jun 2026 Preclinical trials in CNS disorders in USA (unspecified route) (Flavocure Biotech Pipeline, June 2026)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Glioblastoma in USA